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ABSTRACT
White matter hyperintensities (WMH) are often seen on MRI brain scans in frontotemporal dementia
(FTD) due to progranulin (GRN) mutations, but their pathological correlates are unknown. We examined
the histological changes underlying WMH in a patient with GRN mutation associated behavioral variant
FTD. In vivo and cadaveric MRI showed progressive, asymmetric frontotemporal and parietal atrophy,
and asymmetrical WMH predominantly affecting frontal mid-zones. We first performed segmentation
and localization analyses of WMH present on cadaveric MRI FLAIR images, then selected five different
brain regions directly matched to differing severities of WMH for histological analysis. We used
immunohistochemistry to assess vascular pathology, degree of spongiosis, neuronal and axonal loss,
TDP-43, demyelination and astrogliosis, and microglial burden and morphology. Brain regions with
significant WMH displayed severe cortical and white matter pathology, and prominent white matter
microglial activation and microglial dystrophy, but only mild axonal loss and minimal vascular pathol-
ogy. Our study suggests that WMH in GRN mutation carriers are not secondary to vascular pathology.
Whilst cortical pathology induced axonal degeneration could contribute to white matter damage,
individuals with GRN mutations could develop selective white matter vulnerability and myelin loss
due to chronic, regional microglial dysfunction arising from GRN haploinsufficiency.
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Introduction
Cerebral white matter hyperintensities (WMH) reflect an abnor-
mal tissue fat/water ratio within myelinated brain areas, and are
visible as hyperintense lesions on T2-weighted and fluid-attenu-
ated inversion recovery (FLAIR) MRI sequences (Wardlaw, Valdés
Hernández, & Muñoz-Maniega, 2015). WMH appear in healthy
aging as periventricular and deep white matter lesions asso-
ciated with demyelination, microgliosis and vacuolation
(Murray et al., 2012), and in patients with small vessel cerebro-
vascular disease, associated with white matter axonal loss,
demyelination, gliosis, and arteriosclerosis (Wardlaw et al.,
2015). WMH also occur in neuroinflammatory diseases such as
multiple sclerosis (Sarbu et al., 2016), and in neurodegenerative
diseases (Filley & Fields, 2016). Research into the pathological
correlates ofWMH in vascular dementia and sporadic and familial
Alzheimer’s disease (AD) is well-established (McAleese et al.,
2015, 2017; Ryan et al., 2015; Snyder et al., 2015). However,
WMH are less commonly seen in frontotemporal dementia
(FTD). Several studies have now reported prominent WMH in
patients with familial FTD due to progranulin (GRN) mutations
(Caroppo et al., 2014; Ameur et al., 2016; Kelley et al., 2009; Le Ber
et al., 2008; Paternicò et al., 2016; Pietroboni et al., 2011; Sudre
et al., 2017) but the pathological changes underlying these have
not previously been studied in detail.
In order to establish accurately the pathological correlates
of WMH, precise correlation of neuroimaging abnormalities
with histological changes in corresponding brain tissue is
needed. This was previously difficult to establish through use
of in vivo MRI in patients who later came to post-mortem, as
WMH evident on the last available in vivo scan typically did
not match the location and severity of brain tissue abnormal-
ities seen after death. However, use of cadaveric brain MRI
enables scanning of the intact post-mortem brain in situ
within 24 h of death (Tofts et al., 2008). It provides detailed,
undistorted images of the brain, avoiding the changes that
can occur with post-mortem scanning following brain removal
and fixation, and allows precise spatial and quantitative corre-
lations of neuroimaging abnormalities with histological find-
ings. We therefore used this technique to examine the
pathological correlates of WMH in a patient with GRN muta-
tion associated FTD. We first characterized the location and
burden of WMH present on cadaveric MRI then selected sev-
eral different regions of brain tissue for detailed histological
examination, which corresponded closely with presence of
differing severities of WMH. In addition to assessing pathology
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identified in previous studies of WMH in neurodegnerative
disease, we carried out a comprehensive assessment of vas-
cular pathology using recent consensus guidelines (Skrobot
et al., 2016), and, given the role of GRN in microglial function,
examined patterns of several different microglial markers.
Case report
A 60 year-old left-handed female developed progressive beha-
vioral change, speech disturbance and episodic memory
impairment. Initially she developed prominent apathy,
reduced social interaction, sweet tooth, disinhibition, and
new obsessions, followed by reduced speech output and use
of stereotypic phrases. Two years after onset she had difficulty
remembering recent events and conversations, and got lost in
familiar places, then developed dyscalculia. She had occa-
sional visual hallucinations of family members. Her condition
rapidly worsened four years after onset and she was admitted
to a nursing home with impaired spatial awareness, prosopag-
nosia, wandering and incontinence. She later developed an
asymmetrical extrapyramidal syndrome with dystonic limb
movements, worse on the right. She died aged 68 with a
final clinical diagnosis of behavioral variant FTD. The patient
donated her brain for post-mortem analysis to the Queen
Square Brain Bank for Neurological Disorders (QSBB) at
University College London Institute of Neurology.
The patient’s medical history included progressive right-
sided facial hemi-atrophy, diagnosed 15 years prior to onset
of cognitive symptoms, with no cause identified. Two years
after onset of cognitive symptoms she developed a persistent
cough and peripheral eosinophilia, pericardial thickening and
an anterior pericardial effusion. The cause of these symptoms
was not identified despite thorough investigation, but was felt
to be autoimmune in origin. There were no vascular risk
factors, no prior smoking history, and consistently normal
blood pressure. Her mother had developed acute psychosis
with delusions and odd behavior aged 65, followed by pro-
gressive cognitive decline and admission to a mental health
unit for 20 years, with an eventual diagnosis of dementia.
There was no other family history of dementia or neurological
or vascular disease.
Investigations included a volumetric 1.5 T MRI brain per-
formed 2.6 years before the patient died. This showed bilateral
but asymmetric frontal, temporal, and parietal atrophy, worse on
the left, and significant bilateral periventricular WMH, worst in
the frontal lobes and on the left side. Cerebrospinal fluid ana-
lyses were normal or negative. A wide variety of blood tests were
normal, except for peripheral eosinophilia of 1.11 (range 0.0–0.4
x 109/L) and positive rheumatoid positive particle agglutination
test (1/80 titer). DNA analysis identified a heterozygous GRN
Q130fs mutation but no other FTD-associated mutations.
Methods
Imaging analysis
The in vivo 1.5 T MRI was performed on a GE Signa scanner
including volumetric T1, and T2, but not FLAIR, sequences. The
patient had also consented to participation in a cadaveric MRI
study, approved by the National Hospital for Neurology and
Neurosurgery and Institute of Neurology Joint Research Ethics
Committee. A 1.5 T GE Signa MRI scanner was used within 24 h
of her death to perform cadaveric in situ brain MRI, including
volumetric T1 and FLAIR sequences, as described previously
(Tofts et al., 2008).
The in vivo and cadaveric MRI volumetric T1 images were
compared using the Statistical Parametric Mapping (SPM)12
Serial Longitudinal Registration tool (www.fil.ion.ucl.ac.uk/
spm) to estimate the percentage of volumetric contraction
for each voxel between the two scans and assess degree of
brain atrophy over time. Although WMH were present on both
the in vivo and cadaveric MRI, only the cadaveric MRI could be
used for further imaging analysis, due to lack of in vivo FLAIR
and poor quality in vivo T2-weighted imaging. This precluded
quantitative comparison of interval change in WMH between
scans. Regional quantification of WMH in the cadaveric MRI
FLAIR sequence was performed using segmentation and loca-
lization analyses as previously described (Sudre et al., 2017,
2015; Sudre, Cardoso, & Ourselin, 2017) (see Supplementary
Material). This allowed quantification of WMH burden in each
lobe and within different cortical and subcortical “layers”,
guiding selection of regions for histological analysis.
Immunohistochemistry and histological analysis
The brain donation protocol at QSBB was approved by a
London Research Ethics Committee, and the tissue stored for
research purposes under a license from the Human Tissue
Authority. The right hemisphere was fixed and left hemisphere
frozen as per standard protocol, and the right hemisphere cut
into 5mm thick coronal slices. Paraffin-embedded tissue sec-
tions from a large number of brain regions underwent routine
post-mortem analysis, including examination for tau, transac-
tive response DNA binding protein 43 (TDP-43), alpha-synu-
clein and amyloid beta (Aβ) deposition, neuronal, myelin and
axonal loss and astrogliosis (Lashley et al., 2008; Ryan et al.,
2015). The circle of Willis was examined for presence of ather-
oma, and other relevant cortical, subcortical and hippocampal
regions (including leptomeningeal vessels) were examined for
vascular pathology.
Five brain regions were selected for detailed histological
analysis to examine the pathological correlates of differing
severities of WMH. First, we identified brain tissue slices from
the fixed right hemisphere that anatomically matched relevant
cadaveric MRI FLAIR image slices on coronal, sagittal and axial
views (Figure 1). Then we selected five brain regions corre-
sponding to the following degrees of WMH severity, based on
both visual inspection and imaging analyses of cadaveric MRI
FLAIR images: right frontal pole (severe; Figure 1(a)), anterior
frontal lobe (moderate to severe; Figure 1(b)), temporal lobe
(mild to moderate; Figure 1(c)), posterior frontal lobe (very mild;
Figure 1(d)), and occipital lobe (absent/none; Figure 1(e)).
Paraffin-embedded sections were cut from tissue blocks
obtained from each of these regions (Figure 1). Sections were
stained with hematoxylin and eosin (H&E), Luxol fast blue (LFB)
and Perl stains to assess the degree of neuronal loss and spon-
giosis, myelin loss, and hemosiderin deposition.
Immunohistochemistry was performed to detect the presence
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of TDP-43, Aβ, tau, alpha synuclein, phosphorylated neurofila-
ments (axons) and activated astrocytes (see Supplementary
Material).
We performed further immunohistochemistry (see
Supplementary Material) on all five regions to investigate
whether regions with severe WMH were associated with dif-
ferent degrees of microglial burden, activation or morphology,
compared with regions where WMH were milder or absent.
Three antibodies were used to detect microglia with differing
phenotypes, in both ramified and activated states: cluster of
differentiation CD68 (CD68), which detects a lysosomal and
endolyosomal glycoprotein upregulated in activated, phago-
cytic microglia; CR3/43, which detects human leucocyte anti-
gen-DR (HLA-DR), a molecule expressed by microglia with
antigen presenting cell function and upregulated in inflamma-
tion; and ionized calcium-binding adapter molecule 1 (Iba1),
which is expressed by resting microglia but upregulated on
activated microglia, may reflect microglial motility, and is use-
ful for assessing microglial morphology (Minett et al., 2016;
Streit, Braak, Xue, & Bechmann, 2009; Tischer et al., 2016).
Grey and white matter from the five brain regions were
assessed for histological changes through microscopic exam-
ination and consensus opinion of two neuropathologists
blinded to the severity of WMH. Sections were qualitatively
assessed for degree of neuronal loss and spongiosis and semi-
quantitatively assessed for degree of axonal loss, myelin loss,
TDP-43, astrogliosis, and presence of microglia (CD68, CR3/43
and Iba1 positive cells). Semi-quantitative assessment used a
multi-tier scoring system modified from a previous study (Ryan
et al., 2015), where: ‘0ʹ represents no axonal loss, no white
matter pallor, no TDP-43 present, no astrogliosis or no visible
microglia; “+” or ‘1ʹ represents a mild degree of axonal loss,
pallor of the white matter, TDP-43 burden, astrogliosis or
presence of few microglia; “++” or ‘2ʹ represents a moderate
degree of these changes or presence of moderate numbers of
microglia; and “+++” or ‘3ʹ represents a severe degree of these
changes or presence of many microglia. In addition, qualita-
tive descriptions of microglial morphology were recorded, for
example whether microglia appeared amoeboid (round), sug-
gestive of microglial activation, or ramified (with extended
processes), or any other atypical morphological appearances.
Axonal and myelin loss were scored in white matter of each
region, neuronal loss and spongiosis in grey matter, and both
grey and white matter within each region were assessed for
other histological changes, but only scored separately for
microglial markers, or if significant differences in other histo-
logical changes were present.
Vascular pathology was semi-quantitatively assessed in grey
and white matter of all five regions using a comprehensive
scoring system based on the consensus recommendations of
the Vascular Cognitive Impairment Neuropathology Guidelines
(VCING) for staging of cerebrovascular pathology in cognitive
impairment (Skrobot et al., 2016) (see Supplementary Material).
Leptomeningeal vessels were also examined for presence of
atheroma in all five brain regions. Presence of atheroma in
the circle of Willis and vascular changes in other cortical and
subcortical areas had been examined during routine post-mor-
tem. Although the VCING include scores for myelin loss, all
regions were also scored for white matter pallor using our
modified multi-tier scoring system (Ryan et al., 2015) to allow
direct comparison between this score of myelin loss and scores
for non-vascular histological changes.
Results
Imaging findings
The in vivo MRI brain scan showed asymmetric (left worse than
right) frontal, temporal and parietal atrophy (Figure 2).
Between the in vivo and cadaveric MRI there had been volume
loss, particularly affecting left posterior frontal and parietal,
and right frontal, areas (Figure 2 bottom panel). WMH were
present asymmetrically on both in vivo T2 and cadaveric FLAIR
images (Figures 1 and 3), predominantly affecting both frontal
lobes, as confirmed by the localization analysis of cadaveric
FLAIR images (Figure 4). WMH were most severe in the left
frontal pole and anterior frontal lobe (Figures 1, 3, and 4),
matching areas of most significant cortical atrophy (Figures 2
and 3), although were also severe in the right frontal pole and
anterior frontal lobe. WMH were present predominantly in the
intermediate layers (layers two to three) of the frontal lobes,
rather than immediately periventricularly or juxtacortically
(Figure 4). WMH were also seen in the parietal lobes (more
on the left than the right), and to a much lesser extent in the
posterior frontal and temporal lobes, with minimal or no WMH
in the occipital lobes (Figures 1, 3 and 4).
Figure 1. Comparison of brain tissue slices with FLAIR sequences of cadaveric
MRI scan to enable accurate tissue block selection. (a) right frontal pole, (b) right
anterior frontal lobe, (c) right temporal lobe, (d) right posterior frontal lobe and
(e) right occipital lobe. Images in the far left column show where tissue blocks
were obtained from post-mortem brain tissue slices. Right three columns show,
from left to right: cadaveric brain MRI images in the coronal, axial, and sagittal
planes. Green boxes indicate borders of the tissue block cut from this region,
superimposed onto the corresponding tissue slice and MRI image. Red crosses
represent the same anatomical point viewed across all three planes.
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Histological changes and correlation with imaging
Routine post-mortem analysis revealed severe neuronal loss
and spongiosis, particularly in the anterior frontal, temporal
and insular cortices and caudate, and severe myelin loss and
gliosis in the frontal and temporal lobes. There was also
severe myelin loss in the external capsule, extreme capsule
and anterior internal capsule. There was comparatively
milder axonal loss in the frontal and temporal lobes. The
cerebellum and occipital lobes had minimal pathology.
Inclusions of TDP-43 were present in neuronal cytoplasm
and occasional neuronal nuclei, together with TDP-43 posi-
tive neuropil threads, particularly in frontal lobe grey and
white matter, consistent with frontotemporal lobar degen-
eration with TDP (FTLD-TDP) type A pathology (Mackenzie
et al., 2011). There was no Aβ, tau or alpha-synuclein
pathology. There was no atheroma in the vast majority of
leptomeningeal vessels in cortical and subcortical regions
(very rare vessels had atheroma with < 50% vessel occlu-
sion), and no other vascular pathology. There was only mild
(grade 1) atheroma in the circle of Willis.
Results of detailed regional histological analyses are summar-
ized in Table 1, Table 2, Figures 5 and 6. Brain regions with the
most severe WMH (frontal pole and anterior frontal lobe) dis-
played severe white matter pathology, including myelin pallor
and astrogliosis (Table 1; Figure 5(c) and (g)) and severe TDP-43
burden (Table 1) but no or minimal vascular pathology (Table 1)
and relative preservation of axons (Figure 5(e)). Regions with very
mild or absent WMH, such as the posterior frontal lobe or occi-
pital lobe, generally had very mild or no histological changes in
both grey and white matter (Figure 5 (b, d, f, h)). Except for
myelin loss on LFB staining, there were minimal features of
vascular pathology in all regions analyzed (Table 1). There was
very mild arteriolosclerosis present in occasional white matter
vessels in all five brain regions of interest but no atheroma in
leptomeningeal vessels. Brain regions with themost severeWMH
on MRI also displayed the most severe cortical (grey matter)
pathology, including neuronal loss, spongiosis, astrogliosis, and
TDP-43 burden (Table 1). The severity of cortical pathology cor-
responded with the degree of white matter pathology in all
regions analyzed, with the exception of the frontal pole
(Figure 5(e)), anterior frontal lobe and temporal lobe, which
displayed relativelymild axonal loss despitemore severe degrees
of other grey and white matter pathology.
Figure 2. Coronal sections of the in vivo (top row) and cadaveric (second row)
T1-weighted MRI brain scans in the anterio-posterior direction. The third row
shows the longitudinal Statistical Parametric Mapping (SPM) overlay represent-
ing 10% or greater volumetric contraction of the brain on the cadaveric scan,
compared with the in vivo scan, to show interval atrophy, with corresponding
color bar scale.
Figure 3. Axial sections of the in vivo T2-weighted (top row) and cadaveric FLAIR (second row) MRI brain scans. Scans show the change in severity and distribution
of WMH in the 2.6 year interval between scans, in the rostro-caudal direction from (a) to (e). (a) posterior frontal lobes, (b) anterior frontal lobes, (c) frontal poles, (d)
occipital lobes and (e) temporal lobes. R right and L left side of patient.
Figure 4. Bull’s-eye schematic of observed WMH lesion frequency (a), and lesion
distribution (b), within different brain regions and layers in the cadaveric MRI
brain scan. Each region of the brain is apportioned into four layers, with the
ventricle represented at the center of the diagram and the cortical sheet at the
external edge. Lesion frequency is the proportion of the volume of a brain
region taken up by WMH. Lesion distribution is the proportion of the total brain
WMH lesion load present in that region. Degree of lesion frequency and
distribution are represented using a color scale bar. FRONT frontal lobes, PAR
parietal lobes, TEMP temporal lobes, OCC occipital lobes, BGIT basal ganglia and
thalami.
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Patterns of microglia
Microglial burden, activation state and morphology differed
between regions with severe WMH (frontal lobe), and those
without WMH (occipital lobe) (Table 2; Figure 6). There were
generally more CD68, CR3/43 and Iba1 positive microglia pre-
sent in frontal and temporal grey matter than occipital grey
matter (Table 2). There were also more CD68 (Figure 6(a)) and
CR3/43 (Figure 6(c)) positive microglia present in frontal than
occipital white matter (Figure 6 (b) and (d)), but similarly few
Iba1 positive microglia in white matter of both regions
(Figure 6(e) and (f)). Although there were generally more
CD68 and CR3/43 positive microglia present in white matter
than in grey matter of all regions, there were much fewer Iba1
positive microglia in frontal and temporal white matter than
grey matter (Table 2). In the occipital lobe, the burden of Iba1
positive microglia was similar in grey and white matter. In
terms of activation state and morphology, CD68 and CR3/43
positive microglia were amoeboid in appearance in frontal
lobe grey and white matter (Table 2; Figure 6(a) and (c)), but
ramified in occipital grey and white matter (Table 2; Figure 6
(b) and (d)). There was a mixture of amoeboid and ramified
CD68 and CR3/43 positive microglia in regions with intermedi-
ate WMH severity (posterior frontal or temporal lobe; Table 2).
Iba1 positive microglia were also amoeboid in appearance in
frontal grey matter (Table 2). However, in frontal pole and
anterior frontal white matter, where there were significant
WMH, Iba1 positive microglia displayed punctate staining
throughout microglial cell processes, producing a fragmented
appearance, typical of severely dystrophic microglia (Figure 6
Table 1. Histological changes assessed in five brain regions with differing severities of WMH. Scores: + mild, ++ moderate, +++ severe; (0–3) or (0–4) as stated in
table, or in Supplementary Material Table 1. CAA, cerebral amyloid angiopathy; GM, grey matter; WM, white matter.
Brain region Right frontal pole Right anterior frontal lobe Right temporal lobe
Right posterior
frontal lobe
Right occipital
lobe
WMH severity on MRI Severe Moderate to severe Mild to moderate Very mild None
Cortical spongiosis
(None/very mild/mild/
moderate/severe/full
thickness)
Full thickness;
U fibers preserved
Full thickness;
U fibers preserved
Severe Very mild None
Cortical neuronal loss
(No loss/mild/moderate/
severe)
Severe Severe Severe Mild No loss
White matter myelin pallor
(0 = none; 1 = mild;
2 = moderate; 3 = severe)
3 3 3 0 0
White matter axonal loss
(0 = none; 1 = mild;
2 = moderate; 3 = severe)
1 1 1 0 0
Astrogliosis
(0 = none; 1 = mild;
2 = moderate; 3 = severe)
GM: 3
WM:3
GM:3
WM: 3
GM: 1
WM: 3
GM: 1
WM: 3
GM: 1
WM:1
TDP-43 (Type A)
(0/+/++/+++)
++
Moderate cytoplasmic and
nuclear inclusions plus
threads
++/+++
Moderate cytoplasmic and
nuclear inclusions plus
threads
+
Sparse nuclear
inclusions, a few
threads
+
Sparse nuclear
inclusions, a few
threads
+
Only a few
threads
Myelin loss
(0–3)
3 3 3 0 0
Arteriolosclerosis
(0–3)
1 1 1 1 1
Fibrinoid necrosis
(0/1)
0 0 0 0 0
Microaneurysms
(0/1)
0 0 0 0 0
Perivascular space dilation
(0–3)
1 2 2 1 0
Perivascular hemosiderin
leakage
(0–3)
0 1 0 0 0
Microinfarcts
(0/1)
0 0 0 0 0
Lacunar infarcts
(0–3)
0 0 0 0 0
Large infarcts
(0/1)
0 0 0 0 0
Microhemorrhage
(0/1)
0 0 0 0 0
Larger hemorrhage
(0/1)
0 0 0 0 0
Leptomeningeal CAA
(0–4)
0 0 0 0 0
Cortical CAA
(0–4)
0 0 0 0 0
Capillary CAA
(0/1)
0 0 0 0 0
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(e)). This was in contrast to the ramified appearance of Iba1
positive microglia in occipital lobe white matter, where WMH
were absent (Figure 6(f)). Dystrophic microglia were not
observed in frontal grey matter (despite a similar burden of
TDP-43 and other pathology) or in grey matter of any other
region analyzed (Table 2). Microglia were less dystrophic in
white matter within the temporal lobe (moderate WMH) and
posterior frontal lobe (mild WMH).
Discussion
White matter changes such as gliosis and demyelination have
long been observed in histological studies of FTD (Englund &
Brun, 1987) and several groups have observed significant
WMH on MRI brain scans of GRN mutation carriers with FTD
who lack vascular risk factors (Caroppo et al., 2014; Ameur
et al., 2016; Kelley et al., 2009; Le Ber et al., 2008; Paternicò
et al., 2016; Pietroboni et al., 2011; Sudre et al., 2017).
However, studies that have characterized in detail the patho-
logical correlates of WMH in GRN mutation associated FTD
have until now been lacking. Our study used a segmentation
and localization analysis of WMH present on cadaveric MRI
FLAIR images of a patient with GRN mutation associated FTD,
and careful correlation with post-mortem brain tissue, to
enable analysis of the pathological correlates of WMH in
both grey and white matter of several different affected and
unaffected brain regions. Our histological assessment encom-
passed a wide range of morphological vascular changes using
recent consensus guidelines (Skrobot et al., 2016), and other
relevant histological changes examined in previous studies of
WMH in other dementias. In addition, we analyzed the burden,
activation state and morphology of three different microglial
phenotypes across multiple brain regions, which have not
been described previously in FTD. Through this approach we
demonstrate that WMH in GRN mutation associated FTD occur
predominantly in frontal lobe mid-zones and are associated
with significant cortical pathology and white matter demyeli-
nation and gliosis, but only mild axonal loss and minimal
vascular pathology. Microglia expressing Iba1 are severely
dystrophic in regions with significant WMH, such as frontal
white matter, suggestive of regional microglial dysfunction
associated with white matter disease.
Our patient had prominent, asymmetrical WMH on both in
vivo and cadaveric brain MRI. Imaging analysis revealed that
WMH were most prominent in the middle layers of the frontal
lobes, as well as being present in periventricular regions. WMH
were present to a lesser degree in the parietal and temporal
lobes, but were minimal or absent in the occipital lobes. This
pattern of predominantly frontal WMH, extending out into the
Figure 5. Histological changes in a brain region with severe WMH (right frontal
pole; a, c, e, and g) and in a region with no WMH (right occipital lobe; b, d, f and
h). Hematoxylin and eosin staining demonstrates severe grey matter spongiosis
(**) and pallor of the white matter (*) in the frontal pole (a). In the occipital lobe
(b) there is intact cytoarchitecture of the grey matter (**) and white matter (*).
Luxol fast blue staining demonstrates extensive myelin pallor in the white matter
of the frontal pole (c) but intact myelin in the occipital lobe (d). SMI31 immuno-
histochemistry demonstrates relative preservation of axons in the white matter of
both frontal pole (e) and occipital lobe (f). Severe gliosis was present in frontal
pole white matter (g) but only mild in occipital lobe white matter (h). Scale bar in
(a) represents 100µm for (a) and (b), and 10µm for (c) to (h).
Table 2. Microglial burden and morphology in five brain regions with different severities of WMH on MRI. “Amoeboid”: majority of microglia were round. “Ramified”:
majority of microglia had branched processes. “Amoeboid and ramified”: a mixture of both morphologies. “Dystrophic”: punctate staining of microglial cell processes
producing a fragmented, beaded appearance. + few microglia, ++ moderate numbers of microglia, +++ many microglia.
Brain region Right frontal pole Right anterior frontal Right temporal Right posterior frontal Right occipital
Microglial marker WMH severity Severe Moderate to severe Mild to moderate Very mild Absent
CD68 Grey matter +
Amoeboid
++
Amoeboid
+
Amoeboid & Ramified
+
Ramified
+
Ramified
White matter ++
Amoeboid
+++
Amoeboid
+++
Amoeboid & Ramified
+++
Amoeboid & Ramified
++
Ramified
CR3/43 Grey matter +
Amoeboid
+
Amoeboid
++
Amoeboid
++
Amoeboid & Ramified
+
Ramified
White matter ++
Amoeboid
+++
Amoeboid
+++
Amoeboid & Ramified
+++
Ramified
++
Ramified
Iba1 Grey matter +++
Amoeboid
+++
Amoeboid
++
Amoeboid & Ramified
++
Amoeboid
+
Ramified
White matter +
Dystrophic
+
Dystrophic
+
Dystrophic
+
Ramified, few dystrophic
+
Ramified
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“mid-zones” of white matter areas, seems to be a particular
feature of GRN mutation carriers. In a larger study of sympto-
matic and presymptomatic individuals with familial FTD,
symptomatic GRN mutation carriers had increased global
load of WMH compared with MAPT and C9orf72 mutation
carriers (Sudre et al., 2017). WMH were most prominent in
the three layers closest to the lateral ventricles within the
frontal and parietal lobes, and were more homogeneous in
appearance in the GRN mutation group, suggesting a different
aetiology from WMH in other mutation carriers (Sudre et al.,
2017). Similar patterns of WMH were observed in smaller
imaging studies of WMH in GRN mutation carriers (Caroppo
et al., 2014; Ameur et al., 2016).
Through quantitative assessment of regional WMH burden
and atrophy on MRI we determined that the severity of WMH
correlated with the location and extent of cortical atrophy.
This is consistent with correlations described in other imaging
studies (Caroppo et al., 2014; Ameur et al., 2016; Kelley et al.,
2009; Sudre et al., 2017). Using precise anatomical correlation
of cadaveric MRI brain images with tissue slices, we were also
able to demonstrate that regions with the most severe WMH
displayed the most severe cortical pathology on histological
analysis. The severity of white matter pathology also corre-
sponded with the degree of cortical pathology, and WMH
severity, in the majority of brain regions analyzed. This could
suggest that WMH in GRN mutation associated FTD are due to
axonal degeneration and demyelination secondary to cortical
neuronal loss, induced by cortical TDP-43 aggregates. In AD,
cortical hyperphosphorylated tau burden is predictive of the
severity of WMH on MRI, suggesting that cortical tau pathol-
ogy contributes to AD-related WMH (McAleese et al., 2015).
The degree of cortical pathology, demyelination, axonal loss
and Wallerian degeneration also correlates with the extent of
white matter lesions in AD, suggesting a link between grey
matter pathology and white matter damage (McAleese et al.,
2015, 2017). In our study we observed significant cortical TDP-
43 burden and neuronal loss in regions with severe WMH on
MRI (such as the frontal lobe), which correlated with the
severity of demyelination and white matter gliosis in the
same region. However, we did not observe significant axonal
loss in these regions. This suggests that myelin loss alone,
rather than axonal degeneration due to cortical pathology,
may have led to the appearance of WMH on MRI in our case.
An alternative hypothesis is that the prominent WMH in
GRN mutation carriers are secondary to small vessel disease.
However, through comprehensive assessment of multiple
brain regions we demonstrated that there was minimal vas-
cular pathology in our patient, despite presence of significant
other grey and white matter pathology in regions with severe
WMH. Our results suggest that small vessel disease does not
underlie WMH in symptomatic GRN mutation carriers.
Although mild arteriolosclerosis was present, and there was
mild atheroma in rare leptomeningeal vessels in subcortical
regions and the circle of Willis, mild pathological changes such
as these are commonly seen incidentally in healthy aging and
in dementia. In a study of the pathological correlates of WMH
in a mixed cohort of cases (aged controls, AD, and individuals
with significant vascular risk factors) mild arteriosclerosis was
present in 56/57 cases and not significantly different between
those with and without WMH (Shim et al., 2015). A lack of
correlation between markers of ischaemia and small vessel
sclerosis and parietal white matter lesions was observed in
two studies of AD (McAleese et al., 2015, 2017). These studies,
and our findings, underline the importance of not simply
attributing cortical WMH on MRI as due to cerebrovascular
disease when assessing patients with cognitive impairment.
Many patients with sporadic FTD and significant grey and
white matter spongiosis at post-mortem do not display WMH
on MRI. In addition, although white matter disease is generally
more extensive in individuals with FTLD-tau than FTLD-TDP
(Irwin et al., 2018; McMillan et al., 2013), MRI WMH are much
less common in MAPT mutation carriers, who have FTLD-tau,
than GRN mutation carriers, who have FTLD-TDP (Sudre et al.,
2017). Mechanisms independent of FTLD may therefore be
responsible for white matter damage in individuals with GRN
mutations, including mutation-specific mechanisms affecting
white matter vulnerability. Increasing evidence implicates GRN
in regulation of neuroinflammation (Chitramuthu, Bennett, &
Bateman, 2017), particularly in microglial activation and func-
tion (Lui et al., 2016). A study of two GRN mutation carriers
observed significant microgliosis broadly corresponding to
areas of WMH on MRI (Kelley et al., 2009). White matter lesions
in GRN mutation carriers could therefore be due to chronic
neuroinflammation, and we hypothesized that WMH in our
GRN mutation carrier would be associated with regional differ-
ences in microglia. Our analysis used three different microglial
phenotypic markers (CD68, CR3/43 and Iba1) to explore, in
Figure 6. Presence of microglia in right frontal pole white matter (a), (c) and (e),
where there were severe WMH, and right occipital white matter (b), (d) and (f),
where WMH were absent. Images show results of immunohistochemistry for
CD68 (a) and (b), CR3/43 (c) and (d) and Iba1 (e) and (f) positive microglia. There
were more amoeboid microglia in the frontal versus occipital white matter
detected using CD68 (a) versus (b), and CR3/43 (c) versus (d). Iba1 positive
microglia were ramified in occipital white matter (f) but few in number and
severely dystrophic in frontal white matter (e). Scale bar in (a) represents 20µm
in all panels.
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detail, differences in the burden, activation state and morphol-
ogy of between brain regions with and without WMH.
We observed many amoeboid CD68 positive microglia in
both grey and white matter of regions with severe WMH
(frontal lobe) or moderate WMH (temporal lobe), but particu-
larly in white matter. This is consistent with the large number
of activated CD68 positive microglia in GRN mouse models
(Lui et al., 2016; Martens et al., 2012; Yin et al., 2009, 2010) and
patients with GRN mutations, especially in frontal white matter
(Lant et al., 2014; Taipa et al., 2017), which could cause white
matter damage through excessive phagocytosis. We also iden-
tified many amoeboid CR3/43 positive microglia in areas of
severe WMH, suggesting that microglia with antigen-present-
ing cell function were particularly active in these regions,
which has not been described previously in FTD. In the occi-
pital lobe, where WMH were absent, CD68 and CR3/43 positive
microglia were less numerous and more ramified, indicating a
less active phenotype, consistent with minimal other
pathology.
In contrast, there were fewer Iba1 positive microglia in frontal
and temporal white matter than in grey matter. We also
observed severely dystrophic Iba1 positive microglia (Streit
et al., 2009) in frontal and temporal white matter, but not in
occipital lobe white matter, correlating with the presence and
location of WMH. In frontal and temporal grey matter, which
displayed a similar burden of other pathology compared with
white matter, Iba1 positive microglia were typically amoeboid,
rather than dystrophic, in appearance. This dissociation between
degree of microglial dystrophy and other pathology suggests
that there may be region-specific microglial dystrophy in GRN
mutation carriers, perhaps due to premature microglial dysfunc-
tion or senescence (Streit, Xue, Tischer, & Bechmann, 2014)
secondary to GRN haploinsufficiency. As Iba1 expression may
reflect microglial motility (Minett et al., 2016), microglia may be
less motile in frontal white matter of GRN mutation carriers. A
reduction in Iba1 positive microglia was observed in patients
with AD using similar microglial markers (Minett et al., 2016),
and Iba1 positive dystrophic microglia are present in AD cases
(Streit et al., 2009; Tischer et al., 2016), preceding the spread of
tau pathology (Streit et al., 2009). Impaired microglial motility or
function within regions such as frontal and temporal white
matter could reduce neuronal support, leading to white matter
vulnerability in GRN mutation carriers that develop WMH.
Activation of microglia with phagocytic and antigen presenting
cell properties in response to burgeoning protein aggregation
could exacerbate demyelination and white matter damage. This
theory requires further exploration using quantitative measures
of microglial function and motility, as well as burden and
morphology.
Conclusions
Presence of significant MRI WMH in a patient with symptoms of
FTD, a positive family history, and no obvious vascular risk fac-
tors, particularly within frontal white matter, could signal an
underlying GRN mutation and should prompt consideration of
genetic testing (Paternicò et al., 2016). As WMH in our GRN
mutation carrier were not associated with vascular pathology,
they could instead be due to axonal degeneration secondary to
cortical pathology, or region-specific white matter vulnerability,
contributed to by GRN haploinsufficiency and microglial dysfunc-
tion. As our study included only one case, exploration of the
pathological correlates of WMH across a larger cohort of patients
with FTD is needed. Future work should focus on establishing
patterns of grey and white matter pathology and microglial
phenotypes across relevant brain regions in a larger number of
GRN mutation cases, and in individuals with a range of different
subtypes of FTLD, both with and without WMH on MRI.
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